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Loss of amphiregulin reduces myoepithelial
cell coverage of mammary ducts and alters
breast tumor growth
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Abstract
Background: Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, is not only essential for
proper mammary ductal development, but also associated with breast cancer proliferation and growth. In the
absence of AREG, mammary ductal growth is stunted and fails to expand. Furthermore, suppression of AREG
expression in estrogen receptor-positive breast tumor cells inhibits in-vitro and in-vivo growth.
Methods: We crossed AREG-null (AREG−/−) mice with the murine luminal B breast cancer model, MMTV-PyMT
(PyMT), to generate spontaneous breast tumors that lack AREG (AREG−/− PyMT). We evaluated tumor growth,
cytokeratin-8 (K8)-positive luminal cells, cytokeratin-14 (K14)-positive myoepithelial cells, and expression of AREG,
Ki67, and PyMT. Primary myoepithelial cells from nontumor-bearing AREG+/+ mice underwent fluorescence-
activated cell sorting and were adapted to culture for in-vitro coculture studies with AT-3 cells, a cell line derived
from C57Bl/6 PyMT mammary tumors.
Results: Intriguingly, PyMT-induced lesions progress more rapidly in AREG−/− mice than in AREG+/+ mice. Quantification
of K8+ luminal and K14+ myoepithelial cells in non-PyMT AREG−/− mammary glands showed fewer K14+ cells and a
thinner myoepithelial layer. Study of AT-3 cells indicated that coculture with myoepithelial cells or exposure to AREG,
epidermal growth factor, or basic fibroblast growth factor can suppress PyMT expression. Late-stage AREG−/− PyMT
tumors are significantly less solid in structure, with more areas of papillary and cystic growth. Papillary areas appear to be
both less proliferative and less necrotic. In The Cancer Genome Atlas database, luminal-B invasive papillary carcinomas
have lower AREG expression than luminal B invasive ductal carcinomas.
Conclusions: Our study has revealed a previously unknown role of AREG in myoepithelial cell development and PyMT
expression. AREG expression is essential for proper myoepithelial coverage of mammary ducts. Both AREG and
myoepithelial cells can suppress PyMT expression. We find that lower AREG expression is associated with invasive papillary
breast cancer in both the MMTV-PyMT model and human breast cancer.
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Background
Breast cancer remains the most common form of cancer
among women in the USA. In the most recent estimates,
there are over 250,000 new cases and 40,000 new deaths
predicted in 2018 alone [1]. Overexpression of epidermal
growth factor receptor (EGFR) has been shown to be an
important predictor of early recurrence and death in breast
cancer [2, 3]. Historically, patients with positive EGFR sta-
tus were associated with shorter relapse-free and overall
survival. However, therapies targeting EGFR in breast can-
cer have been met with many challenges and little success
[4–6]. Amphiregulin (AREG), a ligand of EGFR, has been
found to be overexpressed in estrogen receptor (ER)-posi-
tive breast cancer [7]. Further evidence shows that loss of
AREG in breast cancer cells can stunt tumor proliferation,
growth, and invasiveness in vitro and in vivo [8–10]. In
addition to breast cancer, AREG has been shown to play an
important role in mammary gland development. During
puberty, AREG is the only EGFR ligand that is transcrip-
tionally activated by estrogen receptor signaling in the
mammary gland [11]. In the absence of AREG, the mam-
mary ductal tree fails to expand and remains as a rudimen-
tary tree throughout adulthood. In mammary gland
transplant studies, epithelial AREG expression and stromal
EGFR expression have been identified as critical for proper
mammary gland development [12]. Interestingly, when
AREG-null epithelial cells are transplanted into a cleared
mammary gland, regardless of EGFR status in the stroma,
the resultant gland shows a lack of cytokeratin-14 (K14)
protein, a marker for myoepithelial cells [13]. While it is
unknown whether AREG supports development and main-
tenance of myoepithelial cells, some evidence suggests that
under low EGFR signaling conditions, mammary stem cells
(MaSCs) preferentially differentiate into luminal, not myoe-
pithelial, cells [14]. In the same study, it was shown that in
the presence of AREG, but not EGF, normal ductal devel-
opment occurred. Therefore, it is possible that AREG is not
only important for the expansion of the ductal tree, but also
for proper differentiation of epithelial progenitor cells into
luminal and myoepithelial cells.
Little is known about how AREG expression alters
breast cancer initiation and progression. In our studies,
we sought to better understand the role of AREG in
breast cancer using the MMTV-PyMT (PyMT) mouse
model. The PyMT model is a widely used murine model
of breast cancer due to its similarities in tumor progres-
sion stages to human breast cancer [15, 16]. Further-
more, activation of PyMT drives many oncogenic
pathways involving key signaling molecules, such as Src,
Ras, and PI3K that are overexpressed in many different
human cancers [17–19]. By crossing PyMT mice with
AREG-null mice, we have evaluated the properties of the
spontaneous PyMT breast tumor model in the absence
of AREG.
In the studies described, we show for the first time
novel functions of AREG in mammary gland develop-
ment, PyMT expression, and breast cancer growth.
Methods
Mice
All animal studies were conducted with approval by the
Albert Einstein College of Medicine Institutional Animal
Care and Use Committee (IACUC). All husbandry was
provided by the Institute of Animal Studies (IAS) under
the supervision of veterinarians at the institution. Mice
were maintained in a pathogen-free facility under con-
trolled light cycles and temperatures. In our animal exper-
iments, we used transgenic mice expressing the polyoma
middle-T antigen (PyMT) controlled by the mammary
tumor virus (MMTV) in the C57Bl/6 background as our
murine breast cancer model. These animals were provided
by Dr Jeffrey W. Pollard at our institution, bred in-house,
and maintained on the C57Bl/6 background. To explore
the role of amphiregulin (AREG) in breast cancer, we used
AREG-knockout (AREG−/−) mice in the same background
[20]. Genotypes of offspring were identified by quantita-
tive PCR (qPCR) via Transnetyx (Cordova, TN, USA).
Lesion growth and histological measurements
Palpable lesion growth was evaluated three times weekly
using a digital caliper. Animals were sacrificed once the
largest lesion reached 1 cm in diameter. Animals whose
lesions ruptured prior to reaching the appropriate size
were excluded from our analyses. AREG−/− lesions had a
greater tendency to be cystic and may have ruptured
more easily than AREG+/+ lesions as they grew bigger.
Lesions were excised and fixed in 10% formalin for 72 h.
Tissues were then embedded in paraffin and serially sec-
tioned for immunohistochemistry and immunofluores-
cence studies. Tumor progression was evaluated by a
breast cancer pathologist (MHO) for presence of hyper-
plasia, ductal carcinoma in situ, and adenocarcinoma in
a blinded fashion. All IHC and H&E staining was per-
formed by the Histology and Comparative Pathology
core facility at Albert Einstein College of Medicine.
Slides were scanned using the 3DHISTECH Pannoramic
250 flash II digital whole slide scanner. Cystic evaluation
was completed by examining 1-cm lesions for the pres-
ence of cysts. If a lesion had at least one cyst, it was con-
sidered cystic in our analysis.
Necrosis analysis
H&E stains of 1-cm AREG+/+ PyMT (N = 32) and AREG−/−
PyMT (N = 22) tumors were evaluated for the presence of
necrosis. Quantification of the percentage of necrosis per
tumor was determined by averaging the percentage of necro-
sis in individual 5× fields. The fields used in the analysis were
determined randomly using a grid placed over the tissue
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image in Pannoramic Viewer so as to select unbiased areas.
Solid and papillary areas were analyzed separately to deter-
mine the amount of necrosis in each type of histological
structure. Statistical analysis was performed using the
Mann–Whitney test.
Circulating tumor cell measurement
The in-vivo intravasation assay for circulating tumor
cells (CTCs) was performed as described previously [21–
24]. A 25-gauge needle and syringe coated with heparin
was inserted into the right ventricle of the heart of anes-
thetized mice and up to 1 ml of blood was collected
from the heart puncture and transferred to a 15-ml tube
with 10 ml of 1× RBC lysis buffer (cat. 00-4300-54; Affy-
metrix). After a 10-min incubation at room temperature,
the cell suspension was pelleted by centrifugation at 200
x g for 5 min. The cell pellet was reconstituted in 10 ml
of Dulbecco’s modified Eagle medium DMEM/F12 (cat.
11320–033; Gibco), supplemented with 20% fetal bovine
serum (FBS)-premium select (cat. S11510; Atlanta Bio-
logicals) and plated in a 10-cm tissue culture-treated
Petri dish. Media were changed after 48 h. After a
1-week incubation, single tumor cells attached on the
dish were counted. Finally, the cell count was normal-
ized to 1 ml of blood.
Metastasis measurements
After mice were sacrificed, the lungs were inflated with
10% formalin and fixed for 72 h. After fixation, the sam-
ples were embedded in paraffin and sectioned. Lungs
were stained with hematoxylin and eosin (H&E). The
number of metastatic foci was counted and their area
was measured.
Carmine staining
The mammary fat pads were evaluated using carmine
staining as described previously [25]. Briefly, glands were
fixed in Carnoy’s fixative overnight at 4 °C. Glands were
rehydrated in serial dilutions of ethanol and rinsed once
with water followed by staining with 0.2% carmine alum
solution overnight at room temperature. The next day,
glands were incubated in 1% HCl/70% EtOH solution
for 4 h to remove the excess carmine stain. Glands were
then dehydrated in increasing concentrations of ethanol.
A 1-h xylene incubation was used to clear the tissue.
Cleared glands were mounted in Permount (cat. SP15–
500; Fisher Scientific). Finally, the slides were scanned
using a conventional digital scanner.
Immunofluorescence
Slides were deparaffinized and stained as described previ-
ously [24]. The following primary antibodies were used:
PyMT (cat. NB100-2749; Novus Biologicals), IBA1 (cat.
NB100-1028; Novus Biologicals), CD31 (cat. 77699; Cell
Signaling), KRT8 (cat. TROMA-I; Developmental Stud-
ies Hybridoma Bank), and KRT14 (cat. 905304; Biole-
gend). After deparaffinization, slides were placed in a
1× target retrieval solution (cat. S169984-2; Agilent
Technologies) and incubated overnight in the Retriever
220 V (cat. 62700-20; Electron Microscopy Sciences)
for antigen retrieval. Slides were washed in 1× PBS and
incubated with blocking buffer (10% donkey serum/
0.1% Triton-X100) for 1 h at 4 °C. Primary antibodies
were diluted in 1× PBS-T at the following concentra-
tions: PyMT 1:100, IBA1 1:100, CD31 1:250, KRT8
1:30, and KRT14 1:1000. Samples were incubated with
primary antibody solutions overnight at 4 °C. Before
secondary antibody incubation, slides were washed
three times in 1× PBS-T for 5 min each. The secondary
antibodies used were Alexa Fluor 647 donkey
anti-rabbit IgG (cat. A31573; Life Technologies), Alexa
Fluor 488 donkey anti-Rat IgG (cat. A21208; Life Tech-
nologies), and Alexa Fluor 568 donkey anti-goat (cat.
A11077; Life Technologies). Secondary antibodies were
diluted in 1× PBS-T at 1:250. Secondary antibody incu-
bation was performed at room temperature for 1 h.
Slides were mounted using Dapi-Fluoromount-G (cat.
OB010020; Southern Biotech) and stored at 4 °C. Slides
were scanned using the 3DHISTECH Pannoramic 250
flash II digital whole slide scanner. The 20 × 0.8 NA ob-
jective lens was used for all scans.
PyMT expression quantitation and analysis
Three to five fields per sample were chosen for ana-
lysis. Images were taken in Pannoramic Viewer and
opened in ImageJ. All images were converted to 8-bit
and the same threshold was applied to all images.
After the threshold was designated, the region of
interest (ROI) covered only the mammary ducts or le-
sions. The surrounding vessels, fat, and stroma were
excluded. The PyMT immunofluorescence intensity
was analyzed only within the ROIs.
In-situ hybridization
In-situ hybridization experiments were performed using
the manufacturer’s protocol for the BaseScope™ Assay
(cat. 322971; ACD). After the signal was detected, the
slides were blocked with 4% donkey serum (cat.
D9663-10ML; Sigma-Aldrich) in 0.1% 1× PBS-T for 1 h
at room temperature. Slides were stained for PyMT
using the protocol described earlier.
Mammary epithelial cell counting and myoepithelial cell
layer thickness measurement
Mammary ducts were immunostained for K8 and K14 to
visualize luminal (K8+) and myoepithelial (K14+) cells.
The ratio of myoepithelial cells to total mammary epi-
thelial cells was counted manually and calculated for five
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ducts per mammary fat pad. At least three AREG+/+
mice and three AREG−/− mice were used for this ana-
lysis. In cases of uncertainty, a confocal microscope was
utilized to differentiate the different cell layers. The out-
lines of myoepithelial cells were traced to calculate the
thickness of the myoepithelial cells.
Mammary epithelial cell isolation
Methods used to retrieve mammary epithelial cells
(MECs) from mice were described previously [26].
Excised mammary glands were placed in ice-cold PBS.
Glands were finely minced on a bacterial Petri dish
and resuspended in 3 ml/mouse DMEM/F12 (cat.
11320-033; Gibco). Then 300 units/ml collagenase III
(cat. LS004182; Worthington), 50 μg/ml DNase I (cat.
LS002139; Worthington), and 5 μM Y-27632 (cat.
Y-5301; LC Labs) were added and incubated at 37 °C
for 2 h under constant rotation. Afterward, the diges-
tion mixture was thoroughly mixed and PBS was
added to 15 ml. The mixture was centrifuged at 300
× g for 5 min. To remove the erythrocytes, the cell
pellet was resuspended with 1 ml RBC lysis buffer
(8.3 g/L ammonium acetate, 10 mM Tris–HCl
pH 7.5) and incubated on ice for 1 min. The cell
mixture was thoroughly mixed, PBS was added to
15 ml, and the mixture was centrifuged again. The
cell pellet was resuspended in 1 ml 0.05% Trypsin–
EDTA (cat. MT25052CI; Corning) and incubated at
37 °C for 5 min. Trypsin was diluted with 10% FBS
in DMEM/F12 and the cell mixture was centrifuged.
To dissociate the luminal and myoepithelial cells, the
cell pellet was resuspended in 1 ml DMEM/F12, 1 U/
ml Dispase (cat. LS02109; Worthington), and 100 μg/
ml DNase. The cell mixture was incubated at 37 °C
for 5 min and passed through a 40-μm cell strainer.
Then 5 ml of PBS was added to the final cell suspen-
sion. The cell number was determined using a
hemocytometer. The cells were centrifuged and resus-
pended in FACS buffer (1 ml FBS, 31 ml PBS, 8 ml
10 mM EDTA) at 1 million cells/100 μl.
Fluorescence-activated cell sorting
To isolate myoepithelial cells from the cell suspension,
the cells were labeled with 1:100 biotin TER-119 (cat.
116204; Biolegend), biotin CD45 (cat. 103104; Biole-
gend), biotin CD31 (cat. 102404; Biolegend), APC
EpCAM (cat. 17–5791-80; Affymetrix), and PerCP-Cy5.5
CD49f (cat. 562475; BD Biosciences). After a 15-min in-
cubation on ice, streptavidin v450 (cat. 560797; BD Bio-
sciences) and 1 μg/ml DAPI (cat. 422801; Biolegend)
were added for another 15-min incubation. Cells were
washed once and resuspended in fluorescence-activated
cell sorting (FACS) buffer. The lineage-negative
(TER-119−CD45−CD31−) EpCAM−CD49f+ cells were
identified as myoepithelial cells.
Cell lines and cell culture
Sorted myoepithelial cells were centrifuged and resus-
pended in 1:20 Matrigel (cat. 354234; Corning) and cul-
tured in advanced-DMEM/F12 (cat. 12634010; Life
Technologies) supplemented with 10 ng/ml EGF (cat.
585506; Biolegend), 20 ng/ml bFGF (cat. 710304; Biole-
gend), 4 μg/ml heparin (cat. H3149-10KU; Sigma-Aldrich),
5% newborn calf serum (cat. SH3011803; HyClone), and
5 μM Y-27632.
AT-3 cells, a murine breast cancer cell line derived
from MMTV-PyMT tumors in the C57Bl/6 back-
ground, were cultured at 7% CO2 in DMEM high glu-
cose (cat. MT-10-013-CV; Corning) supplemented
with 10% FBS premium-select, penicillin–streptomycin
(cat. MT30002CI; Corning), 15 mM HEPES (cat. 15630080;
Life Technologies), 2 mM L-glutamine (cat. SH3003401;
HyClone), NEAA (cat. SH3023801; HyClone), 1 mM sodium
pyruvate (cat. 13-115E; Lonza Walkersville), and 1:250,000
2-mercaptoethanol (cat. M6250-100ML; Sigma Aldrich).
In-vitro experiments
For the coculture experiments, 300,000 primary myoe-
pithelial cells and 300,000 AT-3 cells were plated to-
gether in a six-well tissue culture plate overnight. In the
control well, 300,000 AT-3 cells were plated. Cells were
lysed on the following day using Buffer RLT Plus (cat.
1053393; Qiagen) and RNA was extracted using the
RNeasy Plus Mini Kit (cat. 74134; Qiagen). Subse-
quently, cDNA was synthesized and amplified using the
Superscript II system (cat. 11904-018; Thermofisher
Scientific).
For the stimulation experiments, 300,000 AT-3 cells
were plated overnight. On the following day, the media
were switched to those containing either 10 ng/ml EGF,
10 ng/ml bFGF, 100 ng/ml AREG (cat. 989-AR-100;
R&D Systems), or both EGF and bFGF. Cells were lysed
after a 24-h incubation period.
Quantitative RT-PCR
The gene expression level of PyMT was measured in the
coculture and stimulation experiments using a SYBR
Green Real-Time Master Mix and PyMT primers. The
PyMT primer sequences were TTCGATCCGATCCT
AGATGC and TGCCGGGAACGTTTTATTAG. PyMT
expression was normalized to GAPDH expression. The
GAPDH primer sequences were CTGGAGAAACCTGC
CAAGTA and TGTTGCTGTAGCCGTATTCA. Each
experiment was done in triplicate and repeated at least
three independent times. Relative PyMT expression
levels were derived from the GAPDH mean cycle thresh-
old (Ct) values subtracted by the PyMT Ct values.
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Myoepithelial cells and AT-3 cells had similar levels of
GAPDH. In coculture experiments, ΔCt values were ad-
justed to compensate for a twofold dilution in PyMT ex-
pression level. Changes in relative PyMT expression
levels between experiment and control were measured
as the fold change (ΔΔCt).
TCGA analysis
The Cancer Genome Atlas (TCGA) Research Network
(http://cancergenome.nih.gov/) provided a database of
human breast cancer patient data which we analyzed for
AREG expression and histological subtype. Since the
MMTV-PyMT model was characterized as most similar
to the luminal B subtype in human breast cancer, we
chose our sample population from patient tumors that
were identified as luminal B subtype. With the final sam-
ple of 123 patient samples, 115 were nonpapillary inva-
sive ductal cancer (IDC) and eight were invasive
papillary breast cancer (IPC). AREG RNAseq expression
data provided by TCGA for these patient samples were
then evaluated [27, 28].
Statistical analyses
All statistical analyses were carried out using GraphPad
Prism 7 software. Statistical analyses were performed
using tests as indicated in the figure legends.
Results
Expansion and progression of tumorigenic lesions is
accelerated in the absence of AREG
We examined the role of AREG in breast cancer using the
MMTV-PyMT (PyMT) model in AREG−/− mice. The ap-
pearance of lesions by carmine staining was visible in the
mammary fat pads (MFPs) of both AREG+/+ PyMT
(Fig. 1a) and AREG−/− PyMT (Fig. 1b) females as early as
6 weeks of age. Lesions were larger in AREG−/− PyMT
mice at 6 weeks, and by 12 weeks the difference in size of
the lesions was even more dramatic (Fig. 1c–e). Interest-
ingly, the lesions in AREG+/+ PyMT mice were found in
distinct regions in the ductal tree while in AREG−/− PyMT
mice much of the ductal tree appeared to convert into the
growing lesion. The appearance of multiple lesions in the
AREG+/+ PyMT ductal tree is consistent with previous re-
ports [16]. We measured the growth of palpable lesions in
Fig. 1 In absence of AREG, growth of lesions accelerated. a–d Representative images of carmine-stained AREG+/+ PyMT and AREG−/− PyMT
mammary fat pads at 6 weeks and 12 weeks. Lesions marked by arrows. Scale bar shows 2000 μm. e Total lesion area measured for AREG+/+
PyMT (black bars) and AREG−/− PyMT (gray bars) mice, respectively. At least seven animals measured for 6-week group and at least three animals
for 12-week group. f, g AREG−/− PyMT palpable lesions reached 1-cm diameter more rapidly. f Kaplan–Meier plot of percentage of mice with
palpable lesions less than 1 cm for AREG−/− PyMT mice (dotted line, N = 33) and AREG+/+ PyMT mice (solid line, N = 50). g Mean and SEM of data
in (f). Statistical analysis performed using a log-rank test (f) and t test (e, g). *p < 0.05, **p < 0.01. AREG amphiregulin, PYMT polyoma
middle-T antigen
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AREG+/+ PyMT and AREG−/− PyMT mice three times per
week using a digital caliper until the largest palpable lesion
reached a diameter of 1 cm (Additional file 1: Figure S1).
The largest lesion reached the 1-cm endpoint significantly
faster in AREG−/− PyMT mice (Fig. 1f). The average ages
at which AREG+/+ PyMT mice and AREG−/− PyMT mice
reached the endpoint were 144 days and 134 days, re-
spectively (Fig. 1g).
Consistent with the growth data, tumor progression
was also accelerated in the AREG−/− PyMT mice. Hist-
ology of the lesions was evaluated by a breast cancer
pathologist (MHO). Based on these assessments, the le-
sions of 12-week-old AREG+/+ PyMT mice were found
to be predominantly at the stage of hyperplasia, with
some limited areas of DCIS and invasive carcinoma
(Fig. 2a, c). However, lesions of age-matched AREG−/−
PyMT mice showed more areas that had progressed to
DCIS and invasive carcinoma (Fig. 2b, d, e).
To determine whether AREG-associated effects in
tumor growth and progression were associated with
changes in intravasation and metastasis, we examined
metastases in the lungs as well as circulating tumor cells
(CTCs) in these animals. Overall, we found no difference
in metastasis as measured by the number of foci or total
area in the lungs (Additional file 2: Figure S2A, B) or
number of CTCs (Additional file 2: Figure S2C). In sum-
mary, loss of AREG appears to enhance expansion of
tumorigenic lesions and accelerate tumor progression,
but does not have an effect on intravasation and
metastasis.
Using in-situ hybridization, we confirmed that AREG
is expressed in AREG+/+ animals in the ductal cells and
TEBs, consistent with previous studies (Fig. 3a) [13],
with no expression in AREG−/− animals. We then com-
pared the localization of AREG and PyMT expression in
AREG+/+ PyMT animals and found that they were in-
versely related. PyMT expression was absent in ducts
and TEBs where AREG was expressed, while AREG ex-
pression was rare in hyperplastic and tumor structures
in which PyMT staining was present (Fig. 3a, PyMT
panel).
In both AREG+/+ PyMT and AREG−/− PyMT mammary
glands, all lesions express PyMT (Fig. 3b). Interestingly, the
intensity of PyMT fluorescence in these lesions is similar in
AREG+/+ PyMT and AREG−/− PyMT mammary glands
(Fig. 3c). Since the lesions are larger in AREG−/− PyMT
Fig. 2 Loss of AREG enhances progression to invasive carcinoma. Progression of lesions evaluated based on stages: hyperplasia, ductal carcinoma
in situ (DCIS), invasive carcinoma. a, b Low-magnification representative H&E images of MFPs of 12-week-old AREG+/+ PyMT (a) and AREG−/−
PyMT (b) mice. Scale bar shows 500 μm. c, d High-magnification images of stages of progression as seen in AREG+/+ PyMT (c) and AREG−/− PyMT
(d) mice. Scale bar shows 50 μm. e Greater proportion of AREG−/− lesions identified as invasive carcinomas while most AREG+/+ lesions were
hyperplastic. N = 10. AREG amphiregulin, PYMT polyoma middle-T antigen
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MFPs, this suggests that PyMT is expressed in more areas
in AREG−/− PyMT mammary glands. However, the level of
expression does not differ in the absence of AREG.
Absence of AREG results in reduced myoepithelial cell
number, coverage, and thickness
Even though the ductal tree is much smaller than in the
wildtype, lesion growth in AREG−/− PyMT mice was sig-
nificantly greater. We examined the mammary ducts of
6-week-old and 12-week-old AREG+/+ and AREG−/−
mice in the absence of PyMT to determine whether dif-
ferences in the mammary ducts may explain the en-
hanced lesion growth in AREG−/− mice. We used
cytokeratin-8 (K8) and cytokeratin-14 (K14) staining to
visualize the luminal and myoepithelial layers of the
mammary duct, respectively. The myoepithelial cell layer
in the AREG−/− mice was often discontinuous (Fig. 4a,
arrow) and K14 staining cells could be seen also in the
luminal layer. Overall, the myoepithelial cell layer was
thinner (Fig. 4b, d) and the proportion of K14+ myoe-
pithelial cells was smaller (Fig. 4c, e) in both 6-week-old
and 12-week-old AREG−/− mice. Since it is possible that
PyMT tumors initiate from mature duct termini in
AREG+/+ mice, we compared the proportion of myoe-
pithelial cells in ducts and terminal acini in AREG+/+
mammary glands and found that there were fewer myoe-
pithelial cells in the acini as well (Fig. 4f ).
Because myoepithelial cells are recognized to be tumor
suppressors [29], we hypothesized that myoepithelial cells
might be able to suppress PyMT expression. A reduction
in myoepithelial cells in the AREG−/− mammary ducts
might lead to induction of PyMT expression in more
ductal cells, resulting in more lesion formation in AREG−/
− PyMT mice. To test this hypothesis, we cocultured pri-
mary myoepithelial cells with AT-3 cells, a breast tumor
cell line derived from C57Bl/6 MMTV-PyMT mammary
tumors [30]. When cocultured with primary myoepithelial
cells, PyMT expression in AT-3 cells was significantly re-
duced (Fig. 4g).
In addition, AREG and FGFR signaling are critical for
proper mammary gland elongation and branching [31].
We therefore examined PyMT expression in AT-3 cells
cultured in the presence of the EGFR ligands EGF and
AREG, as well as FGFR ligand bFGF. In the presence of
AREG, EGF, or bFGF, PyMT expression in AT-3 cells
was reduced (Fig. 4h). Therefore, a loss of AREG expres-
sion in vivo could contribute to the broader expression
of PyMT seen in the AREG−/− mice through both a re-
duction in myoepithelial cells as well as reduced EGFR
and FGFR signaling.
Fig. 3 AREG not expressed in PyMT lesions. a Tissue sections hybridized in situ with AREG probe (dots in ducts), and PyMT protein detected by
immunofluorescence. Individual channels shown in gray scale; merged image shows AREG in red and PyMT in green. Ductal structures or lesions
outlined in white, and labeling of surrounding adipose tissue is nonspecific background staining. Scale bar shows 50 μm. b Representative
images of PyMT immunofluorescent staining of 6-week-old AREG+/+ PyMT and AREG−/− PyMT MFPs, respectively. Scale bar shows 100 μm. c At
least 10 mammary glands were analyzed for PyMT staining intensity. Statistical analysis performed using t test. AREG amphiregulin, n.s. not
significant, PYMT polyoma middle-T antigen, TEB terminal end bud
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Late-stage AREG−/− tumors are histologically distinct from
AREG+/+ tumors
Late-stage (1-cm diameter as measured by caliper) AREG+/
+ PyMT tumors are characterized by solid sheets of cells
with occasional ductal structures remaining at the periph-
ery [15]. However, size-matched (1-cm diameter) AREG−/−
PyMT tumors are more heterogeneous in their histology;
they are often composed of both solid and papillary tumor
areas (Fig. 5a). These papillary tumor regions are character-
ized by finger-like fronds that are composed of fibrovascu-
lar stalks lined by neoplastic epithelial cells [32]. When we
compared the percentage of each tumor occupied by solid
or papillary histology, we found that AREG−/− tumors had
a significantly greater proportion of papillary tumor hist-
ology than AREG+/+ tumors (Fig. 5b). We also noticed that
many tumors, particularly AREG−/− tumors, are very cystic
(Additional file 3: Figure S3). If a tumor had at least one
cyst, we characterized that tumor as cystic. Our analysis re-
vealed that while some AREG+/+ tumors are cystic, all of
the AREG−/− tumors had cysts (Fig. 5c). Thus, in addition
to having more papillary features, the AREG−/− tumors are
also more cystic.
To better understand the implications of histological
differences on tumor growth, we assessed AREG+/+ and
AREG−/− tumors for the presence of necrosis (Fig. 6a,
H&E images). In both types of tumors, there is consider-
able variability in the amount of necrosis, ranging from
none at all to over 50% necrotic. Overall, AREG−/− tu-
mors are less necrotic than the wildtype counterpart
(Fig. 6b). When we compared necrotic areas between
solid areas of AREG+/+ tumors and AREG−/− tumors, a
significant difference remains while the papillary areas
have little to no necrosis regardless of AREG status
(Additional file 4: Figure S4). This suggests that the dif-
ferences in necrosis we have observed between AREG+/+
and AREG−/− tumors are due to both an increased pro-
portion of papillary tumor histology (which is not nec-
rotic) as well as reduced necrosis in the solid tumor
regions in the AREG−/− tumors.
We also immunostained these tissues for Ki67 (Fig. 6a,
Ki67 images). We compared the Ki67+ areas in solid and
papillary regions and found that in both AREG+/+ and
AREG−/− tumors, papillary regions have less Ki67 staining
(Fig. 6c, d). Since AREG+/+ tumors are proportionally
Fig. 4 Myoepithelial layer has fewer cells and is thinner in thickness in AREG−/− mice. a Representative images of 12-week-old AREG+/+ (left) and
AREG−/− (right) mammary ducts immunostained with K8 (red) and K14 (green) in merged channel. Arrow indicates discontinuous myoepithelial
layer. Scale bar shows 50 μm. At both 6 weeks (b, c) and 12 weeks (d, e), AREG−/− glands have thinner myoepithelial layer (b, d) and smaller
percentage of K14+ cells (c, e). At least three animals used in each analysis. f Proportion of K14+ cells in ducts and mature duct termini of 12-
week-old AREG+/+ mammary ducts compared (N = 7). g PyMT expression in AT-3 cells suppressed by myoepithelial cells when cocultured. AT-3
cells either cultured alone or with primary myoepithelial cells overnight. RNA extracted and PyMT expression assessed by RT-qPCR. h AT-3 cells
cultured without addition of growth factors (control), with 100 ng/ml AREG, 10 ng/ml EGF, or 10 ng/ml bFGF, or with both EGF and bFGF.
Statistical analysis performed using t test. *p < 0.05, **p < 0.01, ***p < 0.001. AREG amphiregulin, bFGF basic fibroblast growth factor, EGF
epidermal growth factor, PYMT polyoma middle-T antigen
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more solid than AREG−/− tumors, this indicates that, as a
whole, AREG+/+ tumors are more proliferative than
AREG−/− tumors. However, this may be counteracted by
increased necrosis: in the solid areas where tumor prolif-
eration is high, tumor cells far from the blood vessel do
not receive enough oxygen and nutrients and become
hypoxic [33–35]. Rapid growth of the tumor causes ex-
haustion of the nutrients and oxygen supplied by the
nearby blood vessels and, as a result, forms necrotic zones.
Conversely, in the papillary and cystic areas that are more
common in the AREG−/− tumors, there is slower growth,
more stroma, and correspondingly less necrosis.
We used CD31 staining to compare the vasculature be-
tween AREG+/+ and AREG−/− tumors (Additional file 5:
Figure S5A). The vessel structures in AREG+/+ tumors are
thin and long while the vessels in AREG−/− tumors appear
shorter and irregular in shape. These observations are
complemented by quantification of CD31 signals, showing
increased numbers of CD31+ vessels in AREG−/− tumors
(Additional file 5: Figure S5B).
Fig. 6 AREG−/− tumors are less necrotic and tumor cells in papillary regions are less proliferative. a Representative images of H&E (left column)
and Ki67 (right column) staining in AREG+/+ PyMT and AREG−/− PyMT 1-cm tumors. Scale bar shows 500 μm for H&E stains and Ki67 stains. b
Percentage of necrotic areas calculated as average of five fields per AREG+/+ (N = 32) and AREG−/− (N = 22) 1-cm tumors. c, d Ki67+ proliferating
cells in solid vs papillary areas in 1-cm AREG+/+ PyMT and AREG−/− PyMT tumors compared using HistoQuant. Evaluation performed on at least
five separate areas from at least three different tumors per genotype. Statistical analysis performed using t test. *p < 0.05, ***p < 0.001, ****p <
0.0001. AREG amphiregulin, H&E hematoxylin and eosin, PYMT polyoma middle-T antigen
Fig. 5 Late-stage AREG−/− tumors less solid with greater proportion of papillary tumor features. a One-centimeter tumors from AREG+/+ PyMT
(N = 32) and AREG−/− PyMT (N = 22) mice stained with H&E. Scale bars for whole tumors and sections 2000 μm (left) and 100 μm (right),
respectively. b Proportion of solid and papillary tumor areas determined for each tumor. c Proportion of AREG+/+ PyMT (N = 32) and AREG−/−
PyMT (N = 22) tumors that have cysts or no cysts. Statistical analysis performed using Mann–Whitney test (b) and chi-square test (c). **p < 0.01,
****p < 0.0001. AREG amphiregulin, PYMT polyoma middle-T antigen
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Lower AREG expression is associated with papillary breast
cancer
From our results using the PyMT mouse model, we
found that the absence of AREG changes the tumor
histological growth pattern, with AREG−/− tumors devel-
oping with more papillary features. In human breast
cancer, invasive papillary cancer (IPC) is a subtype of in-
filtrating ductal carcinoma (IDC). The genomic profile
of the PyMT mouse model has been characterized as
most similar to the luminal B molecular subtype [36].
Therefore, we examined The Cancer Genome Atlas
(TCGA) for patient samples that have been identified as
luminal B. Using the available pathological reports, the
patient samples were separated into nonpapillary IDC
versus IPC. We then evaluated the AREG expression of
these tumors as provided in TCGA. Interestingly, we
found that patients with IPC have a significantly lower
AREG expression than those with nonpapillary IDC
(Fig. 7), consistent with our results that AREG−/− tumors
are more papillary.
Discussion
In our studies, we found that the loss of AREG resulted
in accelerated expansion of PyMT-positive lesions in the
PyMT mouse model of breast cancer. As early as 6 weeks
of age, lesions in AREG−/− PyMT mice were increasing
in size more quickly. Lesions in both AREG+/+ PyMT
mice and AREG−/− PyMT mice were PyMT-positive.
However, it was unclear why there was a larger
PyMT-positive area in the AREG−/− PyMT mice. When
we compared the cellular composition of the mammary
ducts in AREG+/+ and AREG−/− pubertal and adult mice,
we found that AREG−/− ducts had fewer myoepithelial
cells and thinner myoepithelial cell layers than AREG+/+
ducts. Interestingly, in AREG+/+ PyMT MFPs, the
PyMT-positive lesions do not express AREG. We cocul-
tured primary myoepithelial cells with AT-3 cells, a
breast tumor cell line derived from the MMTV-PyMT
mouse model, and found a significant reduction in
PyMT expression in the AT-3 cells. Furthermore, when
we cultured AT-3 cells with EGFR ligands AREG and
EGF, or FGFR ligand bFGF, PyMT expression was re-
duced. In late-stage AREG−/− tumors, we also found a
striking difference in the tumor growth pattern. Most of
the AREG−/− tumors presented with increased papillary
histology, cysts, and number of intratumoral vessels. Fi-
nally, we compared the tumor histology and AREG ex-
pression of luminal B breast cancer patient samples in
TCGA and found papillary breast cancer was associated
with low AREG expression.
In the PyMT model, PyMT expression in the mammary
gland is driven by the MMTV promoter [37]. Stimulation of
the MMTV promoter is primarily controlled by binding of
glucocorticoid-bound glucocorticoid receptor complexes to
the hormone receptor element in the long terminal repeat
(LTR) region of the MMTV promoter [38, 39]. Interestingly,
EGF has been shown to stimulate tyrosine phosphorylation
of the glucocorticoid receptor in breast epithelial HBL100
cells [40]. As a result of EGF stimulation, binding of dexa-
methasone to the glucocorticoid receptor is reduced [41].
Dexamethasone treatment inhibits proliferation of HBL100
cells. However, adding EGF to the dexamethasone treatment
overcomes dexamethasone-mediated inhibition of cell prolif-
eration. EGF has also been shown to increase the expression
of Egr2, a gene that is inhibited by glucocorticoids [42, 43].
This suggests that activation of the EGFR signaling pathway
can reduce GR signaling, which is important for MMTV
promoter stimulation. Thus, EGF, and possibly AREG, may
suppress PyMT expression through inhibition of glucocorti-
coids binding to its receptor.
It is also possible that loss of AREG alters the balance
of proliferation between different cell types that can con-
tribute to formation of a tumor. AREG expression might
suppress the proliferation of cells with the capability of
driving MMTV promoter activity, and then loss of
AREG could lead to increased proliferation of such cells.
Alternatively, AREG may bias differentiation. The cell
fate of mammary epithelial progenitors has been shown
to be partially dependent on EGFR signaling during
Fig. 7 Lower AREG expression associated with papillary breast
cancer. a AREG expression compared between 115 luminal-B
nonpapillary IDC samples and eight luminal-B IPC samples. b
Representative H&E images of luminal-B IDC and luminal-B IPC.
Statistical analysis performed using Mann–Whitney test. p < 0.0001.
AREG amphiregulin
Mao et al. Breast Cancer Research          (2018) 20:131 Page 10 of 14
development [14]. Under high levels of EGFR activation,
progenitor cells preferentially differentiate into luminal
epithelial cells. The common luminal progenitor gives
rise to both ER-positive and ER-negative ductal cells as
well as ER-negative alveolar cells [44]. Potentially, the
loss of AREG could bias differentiation toward the al-
veolar cell phenotype, resulting in more cells that can
express PyMT. Further studies will be needed to resolve
these possibilities.
Furthermore, we have provided evidence that myoe-
pithelial cells can also reduce PyMT expression. Al-
though the mechanism is unknown, myoepithelial cells
have a plethora of activities and functions, aside from
the canonical mechanical contractile function. In par-
ticular, it has been shown that myoepithelial cells are
tumor suppressors, involved in the inhibition of breast
tumor cell proliferation in vitro and breast tumor growth
in vivo, as well as angiogenesis [45, 46]. Myoepithelial
cells also produce activin, a member of the TGF-β super-
family, which can also inhibit breast cancer cell prolifer-
ation by activating cell cycle arrest mediated by Smads
[47, 48]. In other studies, TGF-β negatively regulates
MMTV expression in a mammary tumor cell line [49].
Therefore, it is possible that myoepithelial cell-secreted
factors may reduce PyMT expression via suppression of
the MMTV promoter.
From our studies, we have developed a model that sum-
marizes our key findings (Fig. 8). As key mediators of
estrogen-induced mammary ductal development, epithelial
AREG and stromal EGFR promote ductal elongation dur-
ing puberty [11, 13]. Paracrine EGFR–FGFR signaling be-
tween mammary epithelial and neighboring stromal cells
has been shown to be critical in proper ductal growth and
branching [31]. In AREG+/+ mice (Fig. 8a, top), AREG stim-
ulates fibroblasts to produce FGFs, which bind to FGF re-
ceptors on the epithelial cells to stimulate ductal growth
and branching. In AREG−/− mice (Fig. 8a, bottom), there is
diminished paracrine signaling between mammary epithe-
lial cells and stromal cells, and as a result the ductal tree
fails to grow beyond the postnatal stage and myoepithelial
cell coverage is reduced in the ducts. In the AREG+/+
PyMT mice (Fig. 8b, top), PyMT expression may be sup-
pressed in ducts and terminal end buds both by myoepithe-
lial cells and growth factors such as AREG, EGF, and bFGF,
or there is suppression of the generation of cells that can
expression PyMT. We propose that in AREG+/+ PyMT
mice, tumors are initiated at mature duct termini where
myoepithelial coverage is lower, giving rise to the observed
multifocal initiation. On the other hand, in the AREG−/−
PyMT mice, both myoepithelial coverage and growth factor
expression are reduced, leading to broader PyMT expres-
sion resulting in increased lesion formation throughout the
ductal tree. As a result, AREG−/− tumors form a wider
range of tumor morphologies, including less aggressive
papillary and cystic structures.
Currently, treatment of breast cancer with receptor
tyrosine kinase (RTK) inhibitors that target EGFR, such
as gefitinib, has been met with mixed success [4–6].
Fig. 8 Working model to explain increased tumor initiation and morphological changes in AREG−/− tumors. (a) In mammary duct in absence of
PyMT (top), myoepithelial cells (green) form continuous layer around luminal epithelial cells. In mature duct termini, myoepithelial layer is
discontinuous. Luminal epithelial cells secrete AREG that binds to EGFR on stromal cells (yellow). Stimulated stromal cells produce FGFR ligands
that bind to FGFR luminal epithelial cells and myoepithelial cells [31, 56]. In absence of AREG (bottom), EGFR/FGFR paracrine loop is interrupted
and impairs proper mammary ductal development. (b) In AREG+/+ PyMT animals (top), PyMT initiates transformation of luminal epithelial cells in
mature duct termini where there are fewer myoepithelial cells. Myoepithelial cells as well as secreted growth factors such as AREG and bFGF
suppress PyMT expression in mammary duct. In AREG−/− PyMT mice (bottom), PyMT expression is more widespread. Due to global reduction in
myoepithelial cells and reduced AREG and FGF expression, oncogenic transformation takes place more broadly in ductal tree. AREG amphiregulin,
FGF basic fibroblast growth factor, PYMT polyoma middle-T antigen
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Getfitnib treatment in patients with hormone
receptor-positive or hormone receptor-negative meta-
static breast cancer is associated with low clinical benefit
rate (CBR). These treatments are also commonly associ-
ated with cutaneous, gastrointestinal, and hair-related
toxicities [50, 51]. Therefore, EGFR-targeted therapies
are not well tolerated and have low efficacy for some pa-
tients. AREG as a novel target for breast cancer therapy
is attractive [52, 53], potentially reducing the side effects
of broad EGFR inhibition while targeting breast tumor
growth that is driven by AREG. One study using an anti-
body against AREG in ovarian cancer xenografts has
successfully reduced tumor growth [54]. In our model,
loss of AREG dramatically altered the histological
morphology seen in late-stage tumors from a solid to a
papillary structure. In human breast cancer, papillary
carcinoma is associated with a higher survival rate than
invasive ductal carcinoma [55]. AREG-targeted therapy
could avoid negative side effects associated with broad
EGFR inhibitors, but could also potentially direct tumor
growth toward a less aggressive pattern.
Conclusions
Our studies demonstrate a novel role of AREG in myoe-
pithelial cell coverage of mammary ducts during devel-
opment. In the PyMT model of breast cancer, we have
shown that myoepithelial cells and growth factors
AREG, EGF, and bFGF suppress PyMT expression.
These findings may explain the accelerated growth and
progression of early-stage AREG−/− tumors in the
MMTV-PyMT model. Interestingly, late-stage AREG−/−
tumors are less proliferative and demonstrate increased
areas of papillary and cystic features. In human breast
cancer, luminal-B IPCs have lower AREG expression
compared to IDCs. Together, our results provide new
insight into the function of AREG in mammary gland
biology, regulation of PyMT, and breast tumor growth.
Additional files
Additional file 1: Figure S1 Growth of AREG+/+ PyMT and AREG−/−
PyMT lesions. Volumes of palpable lesions that could be reproducibly
detected in AREG+/+ PyMT (A, N = 32) and AREG−/− PyMT (B, N = 22)
mice were measured using a digital caliper. (C) Kaplan–Meier plot of
percentage of mice with no palpable lesions. Statistical analysis
performed using a log-rank test (PPTX 143 kb)
Additional file 2: Figure S2 Loss of AREG does not have a significant
effect on tumor cell intravasation and metastasis. (A) Number of
metastatic foci in lungs of AREG+/+ PyMT (N = 16) and AREG−/− PyMT
(N = 9) mice. (B) Total area of all metastatic foci in each lung calculated
for AREG+/+ PyMT (N = 16) and AREG−/− PyMT (N = 9) mice. (C) Blood
collected from right atrium of AREG+/+ PyMT (N = 8) and AREG−/− PyMT
(N = 8) mice, and CTCs counted and number adjusted to 1 ml of blood.
Statistical analysis performed using Mann–Whitney test. n.s. not
significant (PPTX 124 kb)
Additional file 3: Figure S3 Cysts present in AREG+/+ PyMT and AREG−/
− PyMT tumors. H&E stains of AREG+/+ PyMT and AREG−/− PyMT 1-cm tu-
mors show presence of cysts. Scale bar shows 2000 μm (PPTX 2060 kb)
Additional file 4: Figure S4 Necrosis reduced in solid areas of AREG−/−
PyMT tumors. Percentage necrosis in solid and papillary areas of AREG+/+
PyMT (N = 32) and AREG−/− PyMT (N = 22) tumors assessed individually.
Significant differences observed between solid areas of AREG+/+ PyMT
and AREG−/− PyMT tumors. In addition, papillary regions of both tumor
genotypes have little to no necrosis. Statistical analysis performed using
Mann–Whitney test. *p < 0.05, ***p < 0.001, ****P < 0.0001. n.s. not
significant (PPTX 61 kb)
Additional file 5: Figure S5 Loss of AREG is associated with increased
vascular density in late-stage mammary tumors. (A) Representative
images of CD31 staining of AREG+/+ PyMT and AREG−/− PyMT 1-cm
tumors. (B) Compared to AREG+/+ PyMT tumors, more CD31+ vessels per
field in AREG−/− PyMT tumors. Scale bar shows 100 μm. Statistical
analyses performed using a t test. *p < 0.05, N = 3 (PPTX 182 kb)
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